Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome

Yuichiro Yamada1, Shino Takeuchi2, Mamoru Yoneda1

  • 1Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Insights

Atorvastatin reduced inflammation and fibrosis in a rat model of metabolic syndrome. These anti-inflammatory effects are linked to increased AMP-activated protein kinase (AMPK) and decreased nuclear factor-kappa B (NF-κB) activity.

Area of Science:

  • Cardiovascular Pharmacology
  • Metabolic Syndrome Research
  • Inflammation Biology

Background:

  • Statins inhibit cholesterol synthesis and prevent cardiovascular disease.
  • Statins possess cholesterol-independent anti-inflammatory effects with unclear mechanisms.
  • Metabolic syndrome (MetS) models are crucial for studying related pathologies.

Purpose of the Study:

  • To investigate atorvastatin's effects on cardiac and adipose tissue inflammation in a rat model of MetS.
  • To elucidate the molecular mechanisms behind atorvastatin's pleiotropic anti-inflammatory actions.

Main Methods:

  • DS/obese rats, a MetS model, were treated with atorvastatin (6 or 20mg/kg/day).
  • Cardiac and adipose tissue inflammation markers were assessed.
  • Gene expression of peroxisome proliferator-activated receptor γ, adiponectin levels, AMP-activated protein kinase (AMPK), and nuclear factor-kappa B (NF-κB) activities were analyzed.

Main Results:

  • Atorvastatin ameliorated cardiac fibrosis, diastolic dysfunction, oxidative stress, and inflammation.
  • Both cardiac and adipose tissue inflammation were reduced by atorvastatin at both doses.
  • Atorvastatin activated AMPK and inactivated NF-κB in the heart, while modulating these in adipose tissue.

Conclusions:

  • Atorvastatin's anti-inflammatory effects on the heart and adipose tissue in this MetS model are partly due to increased AMPK and decreased NF-κB activity.
  • These findings contribute to understanding the pleiotropic effects of statins beyond cholesterol reduction.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.7K
Inflammation01:38

Inflammation

Overview
62.9K